The lung cancer advocacy organizations that comprise the Lung Cancer Action
Network are concerned about the FDA’s proposed “Framework for Regulatory
Oversight of Laboratory Developed Tests (LDTs)” released in the 2014-10-03 Draft
Guidance. This framework could limit lung cancer patients’ access to molecular
testing essential for guiding treatment and identifying potentially life-saving
therapies. Read more…